Brief: Neurogene Inc - Ended 2023 In A Strong Financial Position With Approximately $200 Million In Cash And Runway Into 2H26

Neurogene

05/01/2024 14:03

Jan 5 (Reuters) - Neurogene Inc  NGNE.O :
    * ENDED 2023 IN A STRONG FINANCIAL POSITION WITH
APPROXIMATELY
$200 MILLION IN CASH AND RUNWAY INTO 2H:26
    * EXPECTS TO REPORT INTERIM CLINICAL DATA FROM COHORT 1 IN
THE
FOURTH QUARTER OF 2024
    * HAS EXTENDED ITS RESEARCH COLLABORATION WITH THE
UNIVERSITY OF
EDINBURGH BY AN ADDITIONAL THREE YEARS
    * UNITED KINGDOM (UK) MEDICINES AND HEALTHCARE PRODUCTS
REGULATORY
AGENCY HAS APPROVED CO’S CLINICAL TRIAL APPLICATION (CTA) FOR
NGN-401

Source text for Eikon:  ID: 
Further company coverage:  NGNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))